<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40185">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01909323</url>
  </required_header>
  <id_info>
    <org_study_id>SMALTO</org_study_id>
    <nct_id>NCT01909323</nct_id>
  </id_info>
  <brief_title>Digestive Tolerance of Maltitol and FOS</brief_title>
  <official_title>Digestive Tolerance and Postprandial Glycaemic and Insulinaemic Responses Evaluation of Different Maltitol/FOS Mixtures in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syral</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beghin-Meiji</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Syral</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Digestive symptoms following consumption of low digestibe carbohydrates are generally
      assessed product by product but several ingredients can be used simultaneously. The study
      aimed at evaluating to digestive tolerance of maltitol and FOS used in a same food.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Composite score of gastrointestinal symptoms in the 24h following the consumption of products</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual scores of gastrointestinal symptoms: bloating, abdominal discomfort, borborygms, flatulences</measure>
    <time_frame>24 and 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequcency and consistency</measure>
    <time_frame>24 &amp; 48 hours</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic response</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Digestive Tolerance in Healthy Adults</condition>
  <arm_group>
    <arm_group_label>sugary dessert cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>maltitol alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>maltitol 85% / FOS 15%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>maltitol 68% / FOS 32%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>maltitol 50% / FOS 50%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOS alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltitol  85% / FOS15%</intervention_name>
    <arm_group_label>maltitol 85% / FOS 15%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltitol alone</intervention_name>
    <arm_group_label>maltitol alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltitol 68% / FOS 32%</intervention_name>
    <arm_group_label>maltitol 68% / FOS 32%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maltitol 50% / FOS 50%</intervention_name>
    <arm_group_label>maltitol 50% / FOS 50%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>FOS alone</intervention_name>
    <arm_group_label>FOS alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugary dessert cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18.5 and 30

          -  normal and regular stool frequency: at least 3 stools per week and no more than 3 per
             days

          -  subjects not sufferinf from a metabolic, functional or inflammatory disease affecting
             intestinal transit and nutrients absorption

          -  subjects not sufferinf from IBS according to Rome III criteria

          -  subjects not using mdeiction which could affect nutrients absoprtion

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gendre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis SAS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis SAS</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 25, 2013</lastchanged_date>
  <firstreceived_date>July 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
